Breast Cancer Res Treat 2009, in press. 39. Baldi A, Spugnini LY2874455 clinical trial EP: Thoracic hemangiopericytoma in a cat. J Sm An Pract 2006, 159: 598–600. 40. Spugnini EP, Dotsinsky I, Mudrov N, Bufalini M, Giannini G, Citro G, Feroce F, Baldi A: Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. In Vivo 2008, 22: 47–50.PubMed 41. Spugnini EP, Dotsinsky I, Mudrov N,

Citro G, Cardelli P, Caruso G, Baldi A: Electrochemotherapy-Induced radiation recall in a cat. In Vivo 2008, 22: 751–753.PubMed 42. Azria D, Magnè N, Zouhair A, Castadot P, Culine S, Ychou M, Stupp R, Van Houtte P, Dubois JB, Ozsahin M: Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005, 31: 555–570.CrossRefPubMed 43. Spugnini EP, Dotsinsky I, Mudrov N, De Luca A, Codini C, Citro G, D’ Avino A, Baldi A: Successful rescue of a apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of

permeabilizing electric pulses (electrochemotherapy). In Vivo 2008, 22: 51–54.PubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions EPS and AB equally contributed to this work, GC supervised the other contributors and critically revised the manuscript.”
“Introduction buy RAD001 Worldwide, liver cancer is the fifth most common malignancy in men and the eighth in women[1]. According to the World Health Organization (WHO), liver cancer is a major health problem and its incidence is increasing[2]. In the United States alone,

it is estimated that there will be 22,620 new cases and 18,160 deaths related to liver cancer in 2009[3]. The major risk factor for liver cancer is the presence of cirrhosis of the liver, largely due to chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection[4]. It is believed that the combined effects of these infections Astemizole account for well over 80% of liver cancer cases worldwide[1]. Through HBV vaccines and screening of blood and blood products for HBV and HCV, primary liver cancer is the first human cancer largely amenable to prevention[1]. With respect to treatment, the plan depends on a number of factors, including the extent of the disease, growth pattern of the tumour and hepatic functional reserve of the patient[5]. In cases of localized resectable liver tumours, standard treatment is surgical resection (partial hepatectomy) in patients without liver cirrhosis and surgical resection or liver transplantation in patients with liver cirrhosis[5].